A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia

Study Status

Open to Enrollment

Study Description

The purpose of this study is to compare the efficacy, safety and tolerability of elacytarbine versus selected alternative therapies used to treat patients with late stage Acute Myeloid Leukemia (AML)

Elacytarabine is an investigational drug which is not commercially available. It consists of a fatty acid that is connected to a drug called cytarabine. Cytarabine is routinely used in the initial treatment of patients with Acute Myeloid Leukemia (AML). A substational portion of AML patients do, however, have a deficient uptake of cytarabine in their leukemic cells due to a lack of a transport protein (called hENT1) in the cell membrane. Due to the connection to the fatty acid, cellular uptake of elacytarabine is independent of this transport protein, which offers a potential advantage for elacytarabine in the treatment of AML.

Disease Status and/or Stage

Acute Myeloid Leukemia (AML)

Sponsor

Clavis Pharma

Key Eligibility

  • Men and women age 18 and older
  • Acute Myeloid Leukemia (AML)
  • Detailed eligibility discussed when you contact the study team

Principal Investigator

Gail Roboz, MD

Contact

Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page